How Eli Lilly’s 170% Mounjaro Price Hike in the UK Impacts Its Current Valuation
If you have been tracking Eli Lilly’s stock lately, you know there has been plenty of chatter, and more than a few eyebrow-raising moves. Deciding what to actually do with LLY can feel like reading one page from a much longer novel. Over the past month, shares saw a notable slide of just over 12%. Zoom out and you will spot major gains over the last several years. Five-year returns top 400%, thanks in no small part to record-setting drug launches and a pipeline that keeps drawing interest from Wall Street.
Recent headlines are adding fuel to the debate. Eli Lilly just raised prices for its sought-after weight-loss drug, Mounjaro, in the UK by up to 170%, stirring new questions about future growth and risk. Meanwhile, the company is…
